ArticleSynthetic and systems biotechnology2027
Metabolic engineering of
Article in Synthetic and systems biotechnology, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In industrial production, the yield of desired targets derived from carbon sources is frequently diminished by the competitive influence of cellular metabolism within microbial cell factories. The bioproduction of l-valine exemplifies a classic process that is confronted with such a dilemma, substantially hindering its economic industrial-scale production. In this study, we aim to engineer a cell factory capable of efficiently synthesizing l-valine with high yield by minimizing the consumption of its precursor pyruvate through the TCA cycle under oxygen-limited conditions. Metabolic engineering-based adaptive laboratory evolution (ALE) under oxygen-limited conditions resulted in the development of an evolved strain ALE2-40 with better cell growth and enhanced l-valine yield. Through comparative omics analysis and validation experiments, it was uncovered that during the ALE process, both pyruvate dehydrogenase activity and NADH availability were significantly improved. Moreover, beneficial targets have the potential to contribute to the NADH and ATP pools, thereby further promoting l-valine synthesis. Based on these results, reverse engineering of the evolved strain ALE2-40 was further conducted. Ultimately, the final strain VAL19 demonstrated remarkable performance, achieving an impressive l-valine titer of 93.7 g/L within 28 h in a 5-L bioreactor under oxygen-limited conditions, with a remarkable yield of 60.4% from glucose-equivalent to 92.9% of the theoretical yield-and a productivity of 3.35 g/L/h. These results set a new benchmark for the fermentative production of l-valine, with the highest yield and productivity reported so far.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.